TELA Bio Inc expected to post a loss of 16 cents a share - Earnings Preview
TELA Bio Inc TELA.O is expected to show a fall in quarterly revenue when it reports results on November 10 for the period ending September 30 2026
The Malvern Pennsylvania-based company is expected to report a 3.4% decrease in revenue to $19.995 million from $20.69 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for TELA Bio Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for TELA Bio Inc is $2.00, about 143.9% above its last closing price of $0.82
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.18 | -0.18 | -0.20 | Missed | -12.2 |
Mar. 31 2026 | -0.19 | -0.19 | -0.21 | Missed | -11.6 |
Dec. 31 2025 | -0.19 | -0.18 | -0.17 | Beat | 6.9 |
Sep. 30 2025 | -0.20 | -0.20 | -0.19 | Beat | 4.5 |
Jun. 30 2025 | -0.18 | -0.18 | -0.22 | Missed | -24.4 |
Mar. 31 2025 | -0.20 | -0.20 | -0.25 | Missed | -27.8 |
Dec. 31 2024 | -0.24 | -0.22 | -0.23 | Missed | -3.2 |
Sep. 30 2024 | -0.42 | -0.40 | -0.42 | Missed | -3.9 |
This summary was machine generated November 6 at 23:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)